Form 4: RELMADA Director Casamento Awarded Stock Rights

RELMADA Therapeutics Director Charles J. Casamento was granted 164,000 Stock Appreciation Rights with an exercise price of $4.06, vesting quarterly starting March 12, 2026.

Summary

• Charles J. Casamento, a Director of RELMADA THERAPEUTICS, INC. (RLMD), was granted 164,000 Stock Appreciation Rights (SARs).
• The transaction date for this grant was December 12, 2025.
• Each SAR has an exercise price of $4.06.
• The SARs will vest in 16 equal quarterly installments, with the first vesting date on March 12, 2026.
• The expiration date for these Stock Appreciation Rights is December 12, 2035.
• Following this transaction, Mr. Casamento beneficially owns 164,000 Stock Appreciation Rights.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive as an insider receiving an equity grant typically signals confidence and aligns interests, though it's a standard compensation event rather than a major operational announcement.

Positives

• The grant of Stock Appreciation Rights aligns the director's financial interests with those of the shareholders, incentivizing long-term company performance.
• The vesting schedule over several years indicates a commitment to retaining key management and directors.

Future Outlook

The vesting schedule for the Stock Appreciation Rights, commencing in March 2026 and extending over several years, indicates a long-term incentive structure for the director, aligning future performance with equity value.

Industry Context

This Form 4 filing is a routine disclosure of an insider equity grant, common in publicly traded companies across various industries, including biotechnology and pharmaceuticals, to incentivize and retain key personnel.

Stakeholder Impact

• Shareholders: The grant of SARs to a director aims to align management's interests with shareholder value creation, as the SARs gain value only if the stock price increases above the exercise price.

Next Steps

• The Stock Appreciation Rights will begin vesting in 16 equal quarterly installments starting March 12, 2026.

Key Dates

Keywords

RELMADA THERAPEUTICS, RLMD, Stock Appreciation Rights, SARs, Insider Transaction, Form 4, Beneficial Ownership, Director Compensation, Equity Grant